C$0.03 0.0 0.0%
Last Trade - 16/09/20
| Market Cap | ÂŁn/a |
| Enterprise Value | ÂŁn/a |
| Revenue | ÂŁ172k |
| Position in Universe | th / 2682 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Mar | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.060 | 0.066 | 0.066 | 0.61 | 0.46 | 0.35 | +42.8% | ||||
| -100.0 | ||||||||||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Pacgen Life Science Corporation, formerly Pacgen Biopharmaceuticals Corporation, is a life sciences company focused on the commercialization of life sciences products and services. The Company has a worldwide license to develop and commercialize an antifungal called P113 (also called PAC-113). It has sublicensed its PAC-113 right to General Biologicals Corporation (GBC), which offers non-prescription over-the-counter (OTC) products containing PAC-113 in Taiwan. P113 is a 12 amino-acid antimicrobial peptide derived from a histatin protein found in saliva. Its P113 is used for the treatment of various oral conditions, as well as vaginal, dermatological and ophthalmic conditions. GBC offers products, such as cosmetic skin-care products, oral hygiene products and intimate hygiene products. The oral healthcare product includes Mr.&Mrs.O. It has conducted a Phase IIb dose-ranging clinical trial for PAC-113. Its oral health and woman health products are in the commercialization stage.
| Last Annual | March 31st, 2020 |
| Last Interim | June 30th, 2020 |
| Incorporated | April 23, 2004 |
| Public Since | April 23, 2004 |
| No. of Shareholders: | n/a |
| No. of Employees: | 10 |
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Index | |
| Exchange | TSX Venture Exchange |
| Shares in Issue | 64,815,969 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
| Address | 701 West Georgia Street Suite 1500, VANCOUVER, V7Y 1C6, Canada |
| Web | http://www.pacgenlife.com/ |
| Phone | +1 604 4364388 |
| Contact | () |
| Auditors | D&H Group LLP |
As of 16/09/20, shares in Pacgen Life Science are trading at C$0.03, giving the company a market capitalisation of ÂŁn/a. This share price information is delayed by 15 minutes.
Shares in Pacgen Life Science are currently trading at C$0.03 and the price has moved by 100% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Pacgen Life Science price has moved by 78.48% over the past year.
There are no analysts currently covering Pacgen Life Science.
Pacgen Life Science is scheduled to issue upcoming financial results on the following dates:
Pacgen Life Science does not currently pay a dividend.
Pacgen Life Science does not currently pay a dividend.
Pacgen Life Science does not currently pay a dividend.
To buy shares in Pacgen Life Science you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Pacgen Life Science are currently trading at C$0.03, giving the company a market capitalisation of ÂŁn/a.
Here are the trading details for Pacgen Life Science:
We were not able to load our ranking data for Pacgen Life Science
We were not able to load any forecast data for Pacgen Life Science.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Pacgen Life Science. Over the past six months, the relative strength of its shares against the market has been 77.64%. At the current price of C$0.03, shares in Pacgen Life Science are trading at % against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We were not able to find PE ratio data for Pacgen Life Science.
We were unable to find the directors for Pacgen Life Science.
Here are the top five shareholders of Pacgen Life Science based on the size of their shareholding:
